Glo-BNHL

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. A Phase II/III, adaptive prospective international multicentre platform clinical trial designed to evaluate the safety and efficacy of novel agents for the treatment of children, adolescents, and young adults with relapsed and/or refractory B-cell non-Hodgkin Lymphoma. The platform consists of three parallel treatment arms, each one investigating a different novel agent in a group of patients.

Disease Stage – Relapsed/ Recurrent

Patient Age Range –  Birth to 25 years of age

Trial sponsors

• National – ANZCHOG
• International – University of Birmingham

Sites

The Children’s Hospital at Westmead

Perth Children’s Hospital

Queensland Children’s Hospital

Starship Hospital